

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|----------------|---|--|---|---|
| Cancer | | | | |
| Bladder cancer | IL-20; IL-20 receptor- α (IL20R1; IL20RA); cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A; CIP1) | <p>Patient sample and cell culture studies suggest inhibiting IL-20 could help treat muscle-invasive bladder cancer. In human bladder cancer tissue, mRNA levels of <i>IL-20</i> and its receptor <i>IL20R1</i> were greater than those in healthy tissue. In cell-based assays, IL-20 stimulation increased migration and invasion of bladder cancer cell lines and expression of the cell cycle inhibitory protein CDKN1A compared with vehicle control administration. In the IL-20-stimulated cells, small interfering RNA against CDKN1A or IL20R1 prevented the increases in invasion and migration. Next steps could include developing pharmacological inhibitors.</p> <p>Novo Nordisk A/S's NN8226, a neutralizing mAb against IL-20, is in Phase II testing to treat rheumatoid arthritis (RA).</p> <p>SciBX 6(5); doi:10.1038/scibx.2013.109 Published online Feb. 7, 2013</p> | Patent and licensing status unavailable | <p>Lee, S.-J. <i>et al. J. Biol. Chem.</i>; published online Dec. 27, 2012; doi:10.1074/jbc.M112.410233</p> <p>Contact: Sung-Kwon Moon, Chungju National University, Chungbuk, South Korea e-mail: sumoon66@dreamwiz.com</p> |